FDA To Review 12 Peptides: What It Means Moving Forward
About this episode
The FDA recently announced it will review the safety and efficacy of a number of powerful peptides. In 2023, based on safety concerns and reports that providers were treating patients irresponsibly, the FDA assigned a number of peptides for Category 2, effectively banning US pharmacies from compounding them. Today, Dr. Seeds addresses the why, the how, and the what’s next.
Learn more about SSRP Institute
Follow for more!
Instagram: @SSRPInstitute | @Redoxmedicalgroup
Youtube: Subscribe Here
Get every episode summarized
Each time Redox Revolution publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Redox Revolution
Two Orthopedic Surgeons Discuss Cellular Medicine: Dr. Seeds and Dr. Rahman in C...
Redox Revolution
Alcohol: The Facts about Use and Abuse
Redox Revolution
Girls and Sports Injuries: Is There An Epidemic We’re Not Paying Attention To?
Redox Revolution
Understanding Hearing Loss as We Age
Redox Revolution